Wall Street analysts predict that Pacira Pharmaceuticals Inc (NASDAQ:PCRX) will report sales of $77.31 million for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for Pacira Pharmaceuticals’ earnings. The highest sales estimate is $82.32 million and the lowest is $75.30 million. Pacira Pharmaceuticals reported sales of $70.93 million during the same quarter last year, which indicates a positive year-over-year growth rate of 9%. The firm is scheduled to issue its next earnings report on Wednesday, August 1st.
According to Zacks, analysts expect that Pacira Pharmaceuticals will report full year sales of $316.09 million for the current year, with estimates ranging from $311.22 million to $329.62 million. For the next year, analysts anticipate that the company will report sales of $366.72 million per share, with estimates ranging from $347.00 million to $412.19 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Pacira Pharmaceuticals.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, May 3rd. The company reported $0.02 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.02. Pacira Pharmaceuticals had a negative return on equity of 5.81% and a negative net margin of 11.45%. The company had revenue of $74.61 million for the quarter, compared to analyst estimates of $73.92 million. During the same quarter last year, the firm earned ($0.19) EPS. Pacira Pharmaceuticals’s revenue for the quarter was up 7.7% compared to the same quarter last year.
Several brokerages have recently weighed in on PCRX. Canaccord Genuity set a $34.00 price objective on Pacira Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, June 29th. Mizuho reissued a “hold” rating and set a $31.00 price objective on shares of Pacira Pharmaceuticals in a report on Friday, June 29th. Zacks Investment Research lowered Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. ValuEngine raised Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 21st. Finally, BMO Capital Markets lifted their price objective on Pacira Pharmaceuticals from $31.00 to $34.00 and gave the stock a “market perform” rating in a report on Monday, April 9th. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company. Pacira Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $45.00.
Shares of NASDAQ:PCRX opened at $33.10 on Thursday. Pacira Pharmaceuticals has a 1-year low of $26.95 and a 1-year high of $51.10. The company has a market cap of $1.34 billion, a PE ratio of -57.07 and a beta of 1.79. The company has a current ratio of 8.66, a quick ratio of 7.83 and a debt-to-equity ratio of 1.00.
In other Pacira Pharmaceuticals news, VP Lauren Bullaro Riker sold 801 shares of the business’s stock in a transaction on Monday, June 4th. The stock was sold at an average price of $33.02, for a total value of $26,449.02. Following the transaction, the vice president now owns 9,641 shares of the company’s stock, valued at $318,345.82. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO David M. Stack sold 18,406 shares of the business’s stock in a transaction on Thursday, June 7th. The stock was sold at an average price of $36.28, for a total value of $667,769.68. Following the completion of the transaction, the chief executive officer now directly owns 91,831 shares in the company, valued at approximately $3,331,628.68. The disclosure for this sale can be found here. In the last three months, insiders sold 49,093 shares of company stock worth $1,700,983. Insiders own 5.90% of the company’s stock.
A number of institutional investors have recently bought and sold shares of PCRX. US Bancorp DE boosted its stake in Pacira Pharmaceuticals by 53.8% in the first quarter. US Bancorp DE now owns 4,292 shares of the company’s stock worth $134,000 after purchasing an additional 1,501 shares in the last quarter. First Republic Investment Management Inc. acquired a new position in Pacira Pharmaceuticals in the fourth quarter worth $201,000. Twin Focus Capital Partners LLC acquired a new position in Pacira Pharmaceuticals in the fourth quarter worth $206,000. Fisher Asset Management LLC boosted its stake in Pacira Pharmaceuticals by 29.6% in the first quarter. Fisher Asset Management LLC now owns 6,848 shares of the company’s stock worth $213,000 after purchasing an additional 1,566 shares in the last quarter. Finally, Redmile Group LLC acquired a new position in Pacira Pharmaceuticals in the fourth quarter worth $237,000.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.